Added value of FDG-PET for detection of progressive supranuclear palsy

J NEUROL NEUROSUR PS. 2024 [Epub ahead of print].

German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson's disease: new spotlights on diagnostic procedures and non-pharmacological interventions

J NEUROL. 2024 [Epub ahead of print].

Guideline "Parkinson's disease" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie): concepts of care

J NEUROL. 2024 [Epub ahead of print].

Premotor cortical beta synchronization and the network neuromodulation of externally paced finger tapping in Parkinson's disease
Gulberti A, Schneider T, Galindo-Leon E, Heise M, Pino A, Westphal M, Hamel W, Buhmann C, Zittel S, Gerloff C, Pötter-Nerger M, Engel A, Moll C
NEUROBIOL DIS. 2024;197:.

Therapeutic use of medical Cannabis in neurological diseases: a clinical update
Hidding U, Mainka T, Buhmann C
J NEURAL TRANSM. 2024;131(2):117-126.

Clinicians' viewpoints on current paradigms of care and research in Parkinson's disease
Müller T, Buhmann C, Delf M, Klostermann F, Kupsch A, Lipp A, Müngersdorf M, von Pannwitz W, Südmeyer M
J NEURAL TRANSM. 2024 [Epub ahead of print].

Factors affecting driving performance in patients with Multiple Sclerosis - still an open question
Seddiq Zai S, das Nair R, Heesen C, Buhmann C, Pedersen A, Pöttgen J
FRONT NEUROL. 2024;15:1369143.

Correction to: Role of dopamine agonists in Parkinson's disease therapy
Woitalla D, Buhmann C, Hilker-Roggendorf R, Höglinger G, Koschel J, Müller T, Weise D
J NEURAL TRANSM. 2024;131(9):1145.

Automatic covariance pattern analysis outperforms visual reading of 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in variant progressive supranuclear palsy
Buchert R, Wegner F, Huppertz H, Berding G, Brendel M, Apostolova I, Buhmann C, Dierks A, Katzdobler S, Klietz M, Levin J, Mahmoudi N, Rinscheid A, Rogozinski S, Rumpf J, Schneider C, Stöcklein S, Spetsieris P, Eidelberg D, Wattjes M, Sabri O, Barthel H, Höglinger G
MOVEMENT DISORD. 2023;38(10):1901-1913.

Blood neurofilament light chain in Parkinson's disease
Buhmann C, Magnus T, Choe C
J NEURAL TRANSM. 2023;130(6):755-762.

Device-Aided Therapies in Parkinson's Disease-Results from the German Care4PD Study
Fründt O, Hanff A, Möhl A, Mai T, Kirchner C, Amouzandeh A, Buhmann C, Krüger R, Südmeyer M
BRAIN SCI. 2023;13(5):.

Prospective controlled study on the effects of deep brain stimulation on driving in Parkinson's disease
Fründt O, Mainka T, Vettorazzi E, Baspinar E, Schwarz C, Südmeyer M, Gerloff C, Zangemeister W, Poetter-Nerger M, Hidding U, Hamel W, Moll C, Buhmann C
NPJ PARKINSONS DIS. 2023;9(1):105.

SAFE-DBS – A monocentric, randomised, blinded evaluation of safinamide in the perioperative period in Parkinsonian patients with deep brain stimulation
Gülke E, Höfs M, Pinnschmidt H, Gulberti A, Moll C, Hidding U, Buhmann C, Heise M, Hamel W, Pötter-Nerger M
MOVEMENT DISORD. 2023;38(Suppl 1):S608-S609.

Combined Short-Pulse and Directional Deep Brain Stimulation of the Thalamic Ventral Intermediate Area for Essential Tremor
Hidding U, Lezius S, Schaper M, Buhmann C, Gerloff C, Pötter-Nerger M, Hamel W, Moll C, Choe C
NEUROMODULATION. 2023;26(8):1680-1688.

Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children-update and practice recommendations
Jost W, Bäumer T, Bevot A, Birkmann U, Buhmann C, Grosheva M, Guntinas-Lichius O, Laskawi R, Paus S, Pflug C, Schroeder A, Spittau B, Steffen A, Wilken B, Winterholler M, Berweck S
FRONT NEUROL. 2023;14:1275807.

Cannabinoide in der Neurologie
Mainka T, Buhmann C
Info Neurol Psych. 2023;25(2):32-41.

P-139 Distinct neural mechanisms of deep brain stimulation and medication on improving predictive timing functions in patients with advanced Parkinson’s disease
Wang P, Gulberti A, Schneider T, Hamel W, Buhmann C, Köppen J, Gerloff C, Westphal M, Moll C, Engel A
CLIN NEUROPHYSIOL. 2023;148:e70-e71.

Brain MRI in Progressive Supranuclear Palsy with Richardson's Syndrome and Variant Phenotypes
Wattjes M, Huppertz H, Mahmoudi N, Stöcklein S, Rogozinski S, Wegner F, Klietz M, Apostolova I, Levin J, Katzdobler S, Buhmann C, Quattrone A, Berding G, Brendel M, Barthel H, Sabri O, Höglinger G, Buchert R
MOVEMENT DISORD. 2023;38(10):1891-1900.

Role of dopamine agonists in Parkinson's disease therapy
Woitalla D, Buhmann C, Hilker-Roggendorf R, Höglinger G, Koschel J, Müller T, Weise D
J NEURAL TRANSM. 2023;130(6):863-873.

Prevalence, clinical presentations and impact on relationship of sexual dysfunction in Parkinson's Disease
Buhmann C
INT REV NEUROBIOL. 2022;162:1-19.

Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)
Buhmann C, Lezius S, Pötter-Nerger M, Gerloff C, Kuhle J, Choe C
MOVEMENT DISORD. 2022;37(2):435-436.

Reply to: "Diabetes and Neuroaxonal Damage in Parkinson's Disease"
Buhmann C, Pötter-Nerger M, Schulz R, Gerloff C, Kuhle J, Choe C
MOVEMENT DISORD. 2022;37(7):1569-1570.

Do Impulse Control Disorders Impair Car Driving Performance in Patients with Parkinson's Disease?
Fründt O, Fadhel M, Heesen C, Seddiq Zai S, Gerloff C, Vettorazzi E, Pöttgen J, Buhmann C
J PARKINSON DIS. 2022;12(7):2261-2275.

Comparison of Montreal cognitive assessment and Mattis dementia rating scale in the preoperative evaluation of subthalamic stimulation in Parkinson's disease
Gülke E, Alsalem M, Kirsten M, Vettorazzi E, Choe C, Hidding U, Zittel-Dirks S, Buhmann C, Schaper M, Gulberti A, Moll C, Hamel W, Koeppen J, Gerloff C, Pötter-Nerger M
PLOS ONE. 2022;17(4):.

Short pulse and directional thalamic deep brain stimulation have differential effects in parkinsonian and essential tremor
Hidding U, Schaper M, Gulberti A, Buhmann C, Gerloff C, Moll C, Hamel W, Choe C, Pötter-Nerger M
SCI REP-UK. 2022;12(1):.

Behandlung der Sialorrhoe mit Botulinum Neurotoxin Typ A – Konsentierte Praxisempfehlungen für Kinder und Erwachsene
Jost W, Bäumer T, Bevot A, Birkmann U, Buhmann C, Grosheva M, Guntinas-Lichius O, Mlynczak U, Paus S, Pflug C, Schröder S, Steffen A, Wilken B, Berweck S
FORTSCHR NEUROL PSYC. 2022;90(5):212-221.

Erratum: Behandlung der Sialorrhoe mit Botulinum Neurotoxin Typ A – Konsentierte Praxisempfehlungen für Kinder und Erwachsene
Jost W, Bäumer T, Bevot A, Birkmann U, Buhmann C, Grosheva M, Guntinas-Lichius O, Mlynczak U, Paus S, Pflug C, Schröder S, Steffen A, Wilken B, Berweck S
FORTSCHR NEUROL PSYC. 2022;90(5):e1.

Stellenwert der COMT-Hemmer in der Therapie motorischer Fluktuationen
Jost W, Buhmann C, Classen J, Eggert K, Kohl Z, Outeiro T, Tönges L, Woitalla D, Reichmann H
NERVENARZT. 2022;93(10):1035-1045.

Retrospektive Langzeitdaten von Patienten mit Parkinsonsyndrom nach STN-THS Implantation mit segmentierten Elektroden: Real-world long-term data of patients with Parkinson’s disease after STN-DBS with segmented electrodes
Kirsten M, Schoenfeldt-Reichmann E, Gulberti A, Gülke E, Hidding U, Buhmann C, Hamel W, Moll C, Gerloff C, Pötter-Nerger M
2022. Deutscher Parkinson Kongress 2022. .

Evaluation of a Visual-Analog Scale (VAS) for Remote DBS Programming (The REMOTE-Trial)
Koeglsperger T, Alesch F, Buhmann C, Kinfe T, Rumpf J, Schnitzler A, Steiger B, Weiss D, Witt K, Mehrkens J, Levin J
2022. Clinical Neurophysiology. e43-e44.

[18F]FDG-PET zur Differenzialdiagnostik und Prognostik der neurodegenerativen Parkinson-Syndrome: Update 2022
Meyer P, Brumberg J, Buhmann C, Buchert R
Angewandte Nuklearmedizin. 2022;45(4):286-296.

Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson's disease in the MARK-PD study
Pötter-Nerger M, Dutke J, Lezius S, Buhmann C, Schulz R, Gerloff C, Kuhle J, Choe C
J NEURAL TRANSM. 2022;129(3):295-300.

Driving ability and predictors for driving performance in Multiple Sclerosis: A systematic review
Seddiq Zai S, Heesen C, Buhmann C, das Nair R, Pöttgen J
FRONT NEUROL. 2022;13:.

Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice
Tönges L, Buhmann C, Klebe S, Klucken J, Kwon E, Müller T, Pedrosa D, Schröter N, Riederer P, Lingor P
J NEURAL TRANSM. 2022;129(9):1201-1217.

Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study)
Uyar M, Lezius S, Buhmann C, Pötter-Nerger M, Schulz R, Meier S, Gerloff C, Kuhle J, Choe C
MOVEMENT DISORD. 2022;37(6):1299-1304.

Fahrtauglichkeit bei Parkinson-Erkrankung
Buhmann C
Neurologie up2date. 2021;2021(2):327-339.

Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study
Choe C, Petersen E, Lezius S, Cheng B, Schulz R, Buhmann C, Pötter-Nerger M, Daum G, Blankenberg S, Gerloff C, Schwedhelm E, Zeller T
PARKINSONISM RELAT D. 2021;85:5-10.

Reply to: "Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease"
Choe C, Pötter-Nerger M, Buhmann C, Blankenberg S, Gerloff C, Schwedhelm E, Zeller T
MOVEMENT DISORD. 2021;36(1):273-274.

Dysphagia Screening in Parkinson's Disease. A diagnostic accuracy cross-sectional study investigating the applicability of the Gugging Swallowing Screen (GUSS)
Frank U, Radtke J, Nienstedt J, Pötter-Nerger M, Schönwald B, Buhmann C, Gerloff C, Niessen A, Flügel T, Koseki J, Pflug C
NEUROGASTROENT MOTIL. 2021;33(5):.

Impact of COVID-19 Pandemic on (Health) Care Situation of People with Parkinson's Disease in Germany (Care4PD)
Fründt O, Hanff A, Mai T, Kirchner C, Bouzanne des Mazery E, Amouzandeh A, Buhmann C, Krüger R, Südmeyer M
BRAIN SCI. 2021;12(1):.

Nichts hilft - ein Fall für Cannabis?
Mainka T, Buhmann C
2021. Parkinson. Eggers C, Buhmann C (Hrsg.). 1. Aufl. Stuttgart: Kohlhammer, 154-163.

Cardiac manifestation is evident in chorea-acanthocytosis but different from McLeod syndrome
Quick S, Heidrich F, Winkler M, Winkler A, Ibrahim K, Linke A, Speiser U, Grabmaier U, Buhmann C, Marxreiter F, Saft C, Danek A, Hermann A, Peikert K
PARKINSONISM RELAT D. 2021;88:90-95.

The ability of the eating assessment tool-10 to detect penetration and aspiration in Parkinson's disease
Schlickewei O, Nienstedt J, Frank U, Fründt O, Pötter-Nerger M, Gerloff C, Buhmann C, Müller F, Lezius S, Koseki J, Pflug C
EUR ARCH OTO-RHINO-L. 2021;278(5):1661-1668.

Short Pulse and Conventional Deep Brain Stimulation Equally Improve the Parkinsonian Gait Disorder
Seger A, Gulberti A, Vettorazzi E, Braa H, Buhmann C, Gerloff C, Hamel W, Moll C, Pötter-Nerger M
J PARKINSON DIS. 2021;11(3):1455-1464.

Cannabis in Parkinson's Disease: The Patients' View
Yenilmez F, Fründt O, Hidding U, Buhmann C
J PARKINSON DIS. 2021;11(1):309-321.

Management of Pain in Parkinson's Disease
Buhmann C, Kassubek J, Jost W
J PARKINSON DIS. 2020;10(s1):S37-S48.

Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease
Choe C, Niemann L, Englisch C, Petersen E, Buhmann C, Pötter-Nerger M, Blankenberg S, Gerloff C, Schwedhelm E, Zeller T
MOVEMENT DISORD. 2020;35(10):1863-1868.

Reply to: "N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease"
Choe C, Petersen E, Pötter-Nerger M, Buhmann C, Blankenberg S, Gerloff C, Schwedhelm E, Zeller T
MOVEMENT DISORD. 2020;35(10):1888.

Dopamine boosts intention and action awareness in Parkinson's disease
Di Costa S, Barow E, Hidding U, Mainka T, Pötter-Nerger M, Buhmann C, Moll C, Haggard P, Ganos C
EXP BRAIN RES. 2020;238(9):1989-1995.

Sex Disparities in the Self-Evaluation of Subthalamic Deep Brain Stimulation Effects on Mood and Personality in Parkinson's Disease Patients
Dietrich A, Koeppen J, Buhmann C, Pötter-Nerger M, Pinnschmidt H, Oehlwein C, Oehlwein M, Mittmann K, Gerloff C, Engel A, Westphal M, Schaper M, Hamel W, Moll C, Gulberti A
FRONT NEUROL. 2020;11:776.

Die Hamburger Parkinson-Tagesklinik: Ein neues Behandlungskonzept an der Grenze zwischen stationärer und ambulanter Versorgung
Fründt O, Veliqi E, Schönwald B, Sychla P, Gerloff C, Buhmann C
FORTSCHR NEUROL PSYC. 2020;88(6):362-373.

Patient's perspectives on shared decision-making in Parkinson's disease
Gülke E, Wargel C, Rahn A, Solari A, Buhmann C, Gerloff C, Heesen C, Pötter-Nerger M
MOVEMENT DISORD. 2020;2020(35):S559-S560.

A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation
Horn M, Gulberti A, Gülke E, Buhmann C, Gerloff C, Moll C, Hamel W, Volkmann J, Pötter-Nerger M
MOVEMENT DISORD. 2020;35(8):1471-1475.

Comparison of omnidirectional versus unidirectional STN-DBS - Impact on gait and balance in Parkinson's disease
Kirsten M, Gulberti A, Gülke E, Buhmann C, Hamel W, Moll C, Gerloff C, Pötter-Nerger M
MOVEMENT DISORD. 2020;35(SI):.

Cannabis in der Neurologie
Mainka T, Buhmann C
PSYCHOPHARMAKOTHERAP. 2020;2020(27):122-127.

Nine-years follow-up of cavernoma located in basal ganglia mimicking Parkinson's disease
Modreanu R, Buhmann C, Hauptmann B
CLIN NEUROL NEUROSUR. 2020;190:105664.

Neurofilament light chain in serum is significantly increased in chorea-acanthocytosis
Peikert K, Akgün K, Beste C, Ziemssen T, Buhmann C, Danek A, Hermann A
PARKINSONISM RELAT D. 2020;80:28-31.

Impact of simultaneous subthalamic and nigral stimulation on dysphagia in Parkinson's disease
Pflug C, Nienstedt J, Gulberti A, Müller F, Vettorazzi E, Koseki J, Niessen A, Flügel T, Hidding U, Buhmann C, Weiss D, Gerloff C, Hamel W, Moll C, Pötter-Nerger M
ANN CLIN TRANSL NEUR. 2020;7(5):628-638.

Recommendations for Standards of Network Care for Patients with Parkinson's Disease in Germany
Prell T, Siebecker F, Lorrain M, Eggers C, Lorenzl S, Klucken J, Warnecke T, Buhmann C, Tönges L, Ehret R, Wellach I, Wolz M
J CLIN MED. 2020;9(5):.

Specialized Staff for the Care of People with Parkinson's Disease in Germany: An Overview
Prell T, Siebecker F, Lorrain M, Tönges L, Warnecke T, Klucken J, Wellach I, Buhmann C, Wolz M, Lorenzl S, Herbst H, Eggers C, Mai T
J CLIN MED. 2020;9(8):.

Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson's disease
van der Vegt J, Hulme O, Madsen K, Buhmann C, Bloem B, Münchau A, Helmich R, Siebner H
NEUROIMAGE-CLIN. 2020;28:102362.

Empfehlung zum differenzierten Einsatz nuklearmedizinischer Diagnostik bei Parkinson-Syndromen
van Eimeren T, Claßen J, Drzezga A, Eggers C, Hilker-Roggendorf R, Klucken J, Koschel J, Meyer P, Redecker C, Theis H, Buhmann C
FORTSCHR NEUROL PSYC. 2020;88(9):609-619.

Pallidal lead placement in dystonia: leads of non-responders are contained within an anatomical range defined by responders
Zittel S, Hidding U, Trumpfheller M, Baltzer V, Gulberti A, Schaper M, Biermann M, Buhmann C, Engel A, Gerloff C, Westphal M, Stadler J, Köppen J, Pötter-Nerger M, Moll C, Hamel W
J NEUROL. 2020;267(6):1663-1671.

Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes
Buchert R, Buhmann C, Apostolova I, Meyer P, Gallinat J
DTSCH ARZTEBL INT. 2019;116(44):747-754.

Pill swallowing in Parkinson's disease: A prospective study based on flexible endoscopic evaluation of swallowing
Buhmann C, Bihler M, Emich K, Hidding U, Pötter-Nerger M, Gerloff C, Niessen A, Flügel T, Koseki J, Nienstedt J, Pflug C
PARKINSONISM RELAT D. 2019;62:51-56.

Is the Munich dysphagia Test–Parkinson's disease (MDT-PD) a Valid screening tool for patients at risk for aspiration?
Buhmann C, Flügel T, Bihler M, Gerloff C, Nießen A, Hidding U, Nienstedt J, Pflug C
PARKINSONISM RELAT D. 2019;61:138-143.

Evidence for the use of cannabinoids in Parkinson's disease
Buhmann C, Mainka T, Ebersbach G, Gandor F
J NEURAL TRANSM. 2019;126(7):913-924.

Discussing sexuality with Parkinson's disease patients: a multinational survey among neurologists
de Rooy F, Buhmann C, Schönwald B, Martinez-Martin P, Rodriguez-Blazquez C, Putter H, Elzevier H, van der Plas A
J NEURAL TRANSM. 2019;126(10):1273-1280.

Quantitative Sensory Testing (QST) in Drug-Naïve Patients with Parkinson's Disease
Fründt O, Grashorn W, Buhmann C, Forkmann K, Mainka T, Bingel U, Schmidt K
J PARKINSON DIS. 2019;9(2):369-378.

Conditioned pain modulation in drug-naïve patients with de novo Parkinson's disease
Grashorn W, Fründt O, Buhmann C, Wrobel N, Schmidt K, Bingel U
Neurol Res Pract. 2019;1:27.

Conditioned pain modulation in drug-naïve patients with de novo Parkinson’s disease
Grashorn W, Fründt O, Buhmann C, Wrobel N, Schmidt K, Bingel U
Neurol Res Pract. 2019;2019:.

The differential role of subthalamic and nigral neurons in gait control in Parkinson's disease patients
Gulberti A, Horn A, Wagner J, Schaper M, Köppen J, Buhmann C, Sharott A, Westphal M, Engel A, Gerloff C, Hamel W, Moll C, Pötter-Nerger M
MOVEMENT DISORD. 2019;2019(34):503.

Modulation of specific components of sleep disturbances by simultaneous subthalamic and nigral stimulation in Parkinson's disease
Hidding U, Gulberti A, Pflug C, Choe C, Horn A, Prilop L, Braaß H, Fründt O, Buhmann C, Weiss D, Westphal M, Engel A, Gerloff C, Köppen J, Hamel W, Moll C, Pötter-Nerger M
PARKINSONISM RELAT D. 2019;62:141-147.

Mapping stimulation-induced beneficial and adverse effects in the subthalamic area of essential tremor patients
Hidding U, Schaper M, Moll C, Gulberti A, Köppen J, Buhmann C, Gerloff C, Pötter-Nerger M, Hamel W, Choe C
PARKINSONISM RELAT D. 2019;64:150-155.

Phase-dependent suppression of beta oscillations in Parkinson's disease patients
Holt A, Kormann E, Gulberti A, Pötter-Nerger M, McNamara C, Cagnan H, Baaske M, Little S, Köppen J, Buhmann C, Westphal M, Gerloff C, Engel A, Brown P, Hamel W, Moll C, Sharott A
J NEUROSCI. 2019;39(6):1119-1134.

Gait Training in Virtual Reality: Short-Term Effects of Different Virtual Manipulation Techniques in Parkinson's Disease
Janeh O, Fründt O, Schönwald B, Gulberti A, Buhmann C, Gerloff C, Steinicke F, Pötter-Nerger M
CELLS-BASEL. 2019;8(5):.

The challenge of pain in the pharmacological management of Parkinson's disease
Jost W, Buhmann C
EXPERT OPIN PHARMACO. 2019;20(15):1847-1854.

Dyskinesia in multiple system atrophy and progressive supranuclear palsy
Jost W, Lingor P, Tönges L, Schwarz J, Buhmann C, Kassubek J, Schrag A
J NEURAL TRANSM. 2019;126(7):925-932.

Voluntary inhibition of involuntary groaning in progressive supranuclear palsy
Mainka T, Hidding U, Buhmann C, Haggard P, Ganos C
MOV DISORD CLIN PRAC. 2019;5(3):325-326.

Predictive clinical factors for penetration and aspiration in Parkinson's disease
Nienstedt J, Bihler M, Niessen A, Plaetke R, Pötter-Nerger M, Gerloff C, Buhmann C, Pflug C
NEUROGASTROENT MOTIL. 2019;31(3):e13524.

Swallowing speed is no adequate predictor of aspiration in Parkinson's disease
Pflug C, Niessen A, Buhmann C, Bihler M
NEUROGASTROENT MOTIL. 2019;31(12):e13713.

Comparison of Mattis and MOCA testing for neuropsychological assessment in the preoperative evaluation of subthalamic nucleus stimulation in Parkinson's disease
Prilop L, Alsalem M, Gulberti A, Gerloff C, Buhmann C, Hamel W, Moll C, Koeppen J, Poetter-Nerger M
2019. MOVEMENT DISORDERS. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, S239-S239.

Das idiopathische Parkinsonsyndrom und Schmerz – diagnostische und therapeutische Ansätze für ein herausforderndes nicht-motorisches Symptom
Buhmann C, Ip C, Oehlwein C, Tönges L, Wolz M, Reichmann H, Kassubek J
FORTSCHR NEUROL PSYC. 2018;86(S 01):S48-S58.

Stress Management Training (SMT) Improves Coping of Tremor-Boosting Psychosocial Stressors and Depression in Patients with Parkinson’s Disease: A Controlled Prospective Study
Buhmann C, Jungnickel D, Lehmann E
PARKINSONS DIS-US. 2018;2018(2018):4240178.

Fahreignung bei Morbus Parkinson: Driving ability in Parkinson’s disease
Buhmann C, Vesper J, Oelsner H
FORTSCHR NEUROL PSYC. 2018;86(1):43-48.

Thalamic short pulse stimulation diminishes adverse effects in essential tremor patients
Choe C, Hidding U, Schaper M, Gulberti A, Köppen J, Buhmann C, Gerloff C, Moll C, Hamel W, Pötter-Nerger M
NEUROLOGY. 2018;91(8):e704-e713.

Towards unambiguous reporting of complications related to deep brain stimulation surgery: A retrospective single-center analysis and systematic review of the literature
Engel K, Huckhagel T, Gulberti A, Pötter-Nerger M, Vettorazzi E, Hidding U, Choe C, Zittel S, Braaß H, Ludewig P, Schaper M, Krajewski K, Oehlwein C, Mittmann K, Engel A, Gerloff C, Westphal M, Moll C, Buhmann C, Köppen J, Hamel W
PLOS ONE. 2018;13(8):e0198529.

The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient care
Fründt O, Mainka T, Schönwald B, Müller B, Dicusar P, Gerloff C, Buhmann C
J NEURAL TRANSM. 2018;125(10):1461-1472.

Cannabis bei Parkinson – Hype oder Heilmittel
Mainka T, Stork J, Hidding U, Buhmann C
FORTSCHR NEUROL PSYC. 2018;86(2):106-116.

Levodopa-induced dystonia in a patient with possible progressive supranuclear palsy with progressive gait freezing
Modreanu R, Özdemir G, Buhmann C, Hauptmann B
J NEUROL SCI. 2018;388:139–140 .

Drooling is no early sign of dysphagia in Parkinson's disease
Nienstedt J, Buhmann C, Bihler M, Niessen A, Plaetke R, Gerloff C, Pflug C
NEUROGASTROENT MOTIL. 2018;30(4):e13259.

Critical Dysphagia is Common in Parkinson Disease and Occurs Even in Early Stages: A Prospective Cohort Study
Pflug C, Bihler M, Emich K, Niessen A, Nienstedt J, Flügel T, Koseki J, Plaetke R, Hidding U, Gerloff C, Buhmann C
DYSPHAGIA. 2018;33(1):41-50.

Pearls & Oysters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy: Eyes up
Schweyer K, Busche M, Hammes J, Zwergal A, Buhmann C, van Eimeren T, Höglinger G
NEUROLOGY. 2018;90(10):482-485.

Spatio-temporal dynamics of cortical drive to human subthalamic nucleus neurons in Parkinson's disease
Sharott A, Gulberti A, Hamel W, Köppen J, Münchau A, Buhmann C, Pötter-Nerger M, Westphal M, Gerloff C, Moll C, Engel A
NEUROBIOL DIS. 2018;112:49-62.

How does it feel to be operated on the brain? Perceived intraoperative stress of movement disorder patients undergoing awake deep brain stimulation surgery
Sieger J, Gulberti A, Köppen J, Pinnschmidt H, Nitzschke R, Schaper M, Braaß H, Buhmann C, Choe C, Hidding U, Zittel S, Engel A, Mehnert A, Gerloff C, Westphal M, Pötter-Nerger M, Hamel W, Moll C
2018. The many faces of Parkinson’s disease – Motor and non ‐ motor symptoms from prodromal to advanced disease stages. .

First report of clinical outcomes resulting from use of directional deep brain stimulation in Parkinson's disease and essential tremor
Braaß H, Venkatesan , Choe C, Hidding U, Schönwald B, Wargel C, Buhmann C, Gulberti A, Moll C, Köppen J, Gerloff C, Hamel W, Pötter-Nerger M
2017. Mov Disord . suppl. Aufl. .

Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy
Buhmann C, Hilker R, Lingor P, Schrader C, Schwarz J, Wolz M, Reichmann H
J NEURAL TRANSM. 2017;124(8):1005-1013.

Adverse events in deep brain stimulation: A retrospective long-term analysis of neurological, psychiatric and other occurrences
Buhmann C, Huckhagel T, Engel K, Gulberti A, Hidding U, Poetter-Nerger M, Goerendt I, Ludewig P, Braass H, Choe C, Krajewski K, Oehlwein C, Mittmann K, Engel A, Gerloff C, Westphal M, Köppen J, Moll C, Hamel W
PLOS ONE. 2017;12(7):e0178984.

Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy
Buhmann C, Wrobel N, Grashorn W, Fründt O, Wesemann K, Diedrich S, Bingel U
J NEUROL. 2017;264(4):758-769.

Altered neural responses to heat pain in drug-naive patients with Parkinson disease
Forkmann K, Grashorn W, Schmidt K, Fründt O, Buhmann C, Bingel U
PAIN. 2017;158(8):1408-1416.

Impact of Combined Subthalamic Nucleus and Substantia Nigra Stimulation on Neuropsychiatric Symptoms in Parkinson's Disease Patients
Hidding U, Gulberti A, Horn A, Buhmann C, Hamel W, Koeppen J, Westphal M, Engel A, Gerloff C, Weiss D, Moll C, Pötter-Nerger M
PARKINSONS DIS-US. 2017;2017:.

Impact of combined subthalamic nucleus and substantia nigra stimulation on neuropsychiatric symptoms in Parkinson’s disease patients
Hidding U, Gulberti A, Horn A, Buhmann C, Hamel W, Köppen J, Westphal M, Engel A, Gerloff C, Weiss D, Moll C, Pötter-Nerger M
PARKINSONS DIS-US. 2017;2017:7306192.

Retinal degeneration in progressive supranuclear palsy measured by optical coherence tomography and scanning laser polarimetry
Stemplewitz B, Kromer R, Vettorazzi E, Hidding U, Frings A, Buhmann C
SCI REP-UK. 2017;7(1):5357.

Morbus Parkinson: Ist mein Patient noch fahrtüchtig?
Buhmann C
Deutsches Ärzteblatt. 2016;113(37 [4]):.

Das idiopathische Parkinson-Syndrom an der Grenze von ambulanter zu stationärer Versorgung
Buhmann C, Baas H, Hahne M, Jost W, Redecker C, Schwarz M, Woitalla D
FORTSCHR NEUROL PSYC. 2016;84 (Suppl 1):S36-40.

The impact of Parkinson disease on patients´ sexuality and relationship
Buhmann C, Dogac S, Vettorazzi E, Hidding U, Gerloff C, Jürgens T
J NEURAL TRANSM. 2016;124(8):983-996.

Interkulturelle Adaption der AIMS in deutscher Sprache: Eine Skala für abnorme unwillkürliche Bewegungen: Eine Skala für abnorme unwillkürliche Bewegungen
Buhmann C, Rizos A, Emmans D, Jost W
NERVENARZT. 2016;87(4):411-7.

STN-DBS Reduces Saccadic Hypometria but Not Visuospatial Bias in Parkinson's Disease Patients
Fischer P, Ossandón J, Keyser J, Gulberti A, Wilming N, Hamel W, Köppen J, Buhmann C, Westphal M, Gerloff C, Moll C, Engel A, König P
FRONT BEHAV NEUROSCI. 2016;10:85.

Effects of levodopa, low-frequency and high-frequency STN-DBS on auditory-motor synchronization in Parkinson’s disease
Gulberti A, Schneider T, Galindo-Leon E, Pino A, Hamel W, Buhmann C, Pötter-Nerger M, Köppen J, Westphal M, Gerloff C, Engel A, Moll C
2016. International DBS Symposium Clinical Research Group KFO 247. .

Evaluation of Retinal Vessel Morphology in Patients with Parkinson's Disease Using Optical Coherence Tomography
Kromer R, Buhmann C, Hidding U, Keserü M, Bittersohl D, Hassenstein A, Stemplewitz B
PLOS ONE. 2016;11(8):e0161136.

Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease
Ossig C, Antonini A, Buhmann C, Classen J, Csoti I, Falkenburger B, Schwarz M, Winkler J, Storch A
J NEURAL TRANSM. 2016;123(1):57-64.

Detection of retinal changes in idiopathic Parkinson's disease using high-resolution optical coherence tomography and heidelberg retina tomography
Bittersohl D, Stemplewitz B, Keserü M, Buhmann C, Richard G, Hassenstein A
ACTA OPHTHALMOL. 2015;93(7):E578-E584.

Visual Attention and Saccadic Oculomotor Control in Parkinson's Disease
Buhmann C, Kraft S, Hinkelmann K, Krause S, Gerloff C, Zangemeister W
EUR NEUROL. 2015;73(5-6):283-293.

Impact of Deep Brain Stimulation on Daily Routine Driving Practice in Patients with Parkinson's Disease
Buhmann C, Vettorazzi E, Oehlwein C, Rikkers F, Poetter-Nerger M, Gulberti A, Gerloff C, Moll C, Hamel W
PARKINSONS DIS-US. 2015;2015:608961.

Adverse events associated with deep brain stimulation surgery and ongoing treatment
Engel A, Köppen J, Buhmann C, Moll C, Huckhagel T, Westphal M, Hamel W
2015. 66th Annual Meeting of the German Society of Neurosurgery (DGNC). .

Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients
Grashorn W, Schunke O, Buhmann C, Forkmann K, Diedrich S, Wesemann K, Bingel U
PLOS ONE. 2015;10(8):e0135287.

Predictive timing functions of cortical beta oscillations are impaired in Parkinson´s disease and influenced by L-DOPA and deep brain stimulation of the subthalamic nucleus
Gulberti A, Moll C, Hamel W, Buhmann C, Köppen J, Boelmans K, Zittel-Dirks S, Gerloff C, Westphal M, Schneider T, Engel A
NEUROIMAGE-CLIN. 2015;(9):436-449.

Synchronized cortico-subthalamic beta oscillations in Parkin-associated Parkinson's disease
Moll C, Buhmann C, Gulberti A, Fickel U, Poetter-Nerger M, Westphal M, Gerloff C, Hamel W, Engel A
CLIN NEUROPHYSIOL. 2015;126(11):2241-3.

Wie hilfreich ist High-Tech? Entwicklungen der Tiefen Hirnstimulation bei der Parkinson-Krankheit
Pötter-Nerger M, Moll C, Gulberti A, Hamel W, Köppen J, Ludewig P, Hidding U, Goerendt I, Gerloff C, Buhmann C
Neuro aktuell. 2015;(7):21-25.

Effect of neurostimulation on camptocormia in Parkinson's disease depends on symptom duration
Schulz-Schaeffer W, Margraf N, Munser S, Wrede A, Buhmann C, Deuschl G, Oehlwein C
MOVEMENT DISORD. 2015;30(3):368-72.

Scanning laser polarimetry and spectral domain optical coherence tomography for the detection of retinal changes in Parkinson's disease
Stemplewitz B, Keserü M, Bittersohl D, Buhmann C, Skevas C, Richard G, Hassenstein A
ACTA OPHTHALMOL. 2015;93(8):e672-7.

Effects of dopaminergic treatment on functional cortico-cortical connectivity in Parkinson's disease
Zittel-Dirks S, Heinbokel C, van der Vegt J, Niessen E, Buhmann C, Gerloff C, Siebner H, Münchau A, Bäumer T
EXP BRAIN RES. 2015;233(1):329-37.

Could deep brain stimulation help with driving for patients with Parkinson's?
Buhmann C, Gerloff C
EXPERT REV MED DEVIC. 2014;11(5):427-429.

Effect of subthalamic nucleus deep brain stimulation on driving in Parkinson disease
Buhmann C, Maintz L, Hierling J, Vettorazzi E, Moll C, Engel A, Gerloff C, Hamel W, Zangemeister W
NEUROLOGY. 2014;82(1):32-40.

Imaging pain anticipation and pain perception in drug-naïve patients with idiopathic Parkinson’s disease
Forkmann K, Grashorn W, Schmidt K, Buhmann C, Bingel U
CLIN NEUROPHYSIOL. 2014;(125):129.

Tiefe Hirnstimulation: Neurophysiologische Therapie bei M. Parkinson und anderen neurologischen Erkrankungen. Ablauf und Ergebnisse
Goerendt I, Moll C, Fickel U, Gerloff C, Gulberti A, Hidding U, Köppen J, Pötter-Nerger M, Engel A, Westphal M, Buhmann C, Hamel W
Hamb Ärztebl. 2014;68(01):12-17.

Subthalamic deep brain stimulation improves auditory sensory gating deficit in Parkinson's disease
Gulberti A, Hamel W, Buhmann C, Boelmans K, Zittel-Dirks S, Gerloff C, Westphal M, Engel A, Schneider T, Moll C
CLIN NEUROPHYSIOL. 2014;126(3):565-574.

Asymmetric pallidal neuronal activity in patients with cervical dystonia
Moll C, Galindo-Leon E, Sharott A, Gulberti A, Buhmann C, Koeppen J, Biermann M, Bäumer T, Zittel S, Westphal M, Gerloff C, Hamel W, Münchau A, Engel A
Front Syst Neurosci. 2014;8:15.

Wann sind Pflaster, Pens oder Pumpen eine sinnvolle Ergänzung zur oralen Therapie?
Pötter-Nerger M, Ludewig P, Hidding U, Goerendt I, Gerloff C, Buhmann C
Info Neurol Psych. 2014;16(12):42-53.

Activity parameters of subthalamic nucleus neurons selectively predict motor symptom severity in Parkinson's disease
Sharott A, Gulberti A, Zittel-Dirks S, Tudor Jones A, Fickel U, Münchau A, Köppen J, Gerloff C, Westphal M, Buhmann C, Hamel W, Engel A, Moll C
J NEUROSCI. 2014;34(18):6273-6285.

Die Psyche im Blick - Neuropsychiatrische Störungen bei M. Parkinson.
Buhmann C
Der Hausarzt. 2013;10:40-44. .

Das „aut idem“ Problem in der Parkinson Therapie
Buhmann C, Bilsing A, Fuchs G, Jost W, Müngersdorf M
AKTUEL NEUROL. 2013;40:333-337.

Autofahren bei M. Parkinson.
Buhmann C, Gerloff C
AKTUEL NEUROL. 2013;40:315-320.

Driving simulator performance of patients with Parkinson´s disease and subthalamic nucleus deep brain stimulation
Buhmann C, Maintz L, Hierling J, Vettorazzi E, Gerloff C, Hamel W, Zangemeister W
BASAL GANGLIA. 2013;(3):53-54.

Deep brain stimulation of the ventrolateral thalamic base and posterior subthalamic area in dystonic head tremor
Buhmann C, Moll C, Zittel-Dirks S, Münchau A, Engel A, Hamel W
ACTA NEUROCHIR SUPPL. 2013;117:67-72.

Idiopathisches Parkinson-Syndrom und Melanom: erhöhte Koinzidenz und Zusammenhang mit L-Dopa?
Michelmann S, Moll I, Buhmann C, Koch M, Hauswirth U
AKTUEL NEUROL. 2013;40:309-314.

STN stimulation in general anaesthesia: evidence beyond 'evidence-based medicine'
Moll C, Payer S, Gulberti A, Sharott A, Zittel-Dirks S, Boelmans K, Köppen J, Gerloff C, Westphal M, Engel A, Oehlwein C, Buhmann C, Hamel W
ACTA NEUROCHIR SUPPL. 2013;117:19-25.

Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease
van der Vegt J, Hulme O, Zittel-Dirks S, Madsen K, Weiss M, Buhmann C, Bloem B, Münchau A, Siebner H
BRAIN. 2013;136(Pt 4):1192-203.

Quantitative assessment of driving performance in Parkinson's disease (PD) with and without medication or subthalamic nucleus (STN) stimulation
Zangemeister W, Wriedt T, Buhmann C
Schriftenreihe Fahreignung . 2013;134-136.

Improving the differential diagnosis of parkinsonian syndromes in clinical practice
Buhmann C
Parkinson´s Europe. 2012;4(01):4-7.

Effect of subthalamic nucleus deep brain stimulation (DBS) on driving ability in patients with Parkinson´s disease
Buhmann C, Maintz L, Hierling J, Vettorazzi E, Gerloff C, Hamel W, Zangemeister W
AKTUEL NEUROL. 2012;(Suppl. zum Kongreß):.

Depression and quality of life in monogenic compared to idiopathic, early-onset Parkinson's disease.
Kasten M, Kertelge L, Tadic V, Brüggemann N, Schmidt A, van der Vegt J, Siebner H, Buhmann C, Lencer R, Kumar K, Lohmann K, Hagenah J, Klein C
MOVEMENT DISORD. 2012;27(6):754-759.

M. Parkinson früh behandeln - Medikamentöse Therapie sofort nach der Diagnosestellung einleiten
Rosenkranz M, Buhmann C
Der Hausarzt. 2012;11:48-51.

Deficient coordination of gaze-hand-feet-control with a deactivated sub-thalamic nucleus stimulator: Driving performance in Parkinson’s disease
Zangemeister W, Maintz L, Buhmann C
NCM (Neural Control of Movement Society). 2012;(15):61.

Fortbildung. CME-Fortbildung Neurologie. Wirkungsfluktuationen bei Morbus Parkinson
Buhmann C
Info Neurol Psych. 2011;13(6):28.

Deep brain stimulation of the subthalamic nucleus normalises Parkinson‘s disease related abnormalities of auditory evoked potentials and quantitative EEG
Gulberti A, Moll C, Schneider T, Hamel W, Muenchau A, Buhmann C, Boelmans K, Zittel S, Gerloff C, Westphal M, Engel A
2011. 62nd Annual Meeting of the German Society of Neurosurgery (DGNC). .

Depression in Parkinson's disease
Schwarz J, Odin P, Buhmann C, Csoti I, Jost W, Wüllner U, Storch A
BRAIN. 2011;258(Suppl 2):S336-8.

Influence of STN-Stimulation on Parkinson Patients` Simulator Driving
Zangemeister W, Maintz L, Hierling J, Buhmann C
NCM (Neural Control of Movement Society). 2011;(14):41.

Anwendung von transdermalem Rotigotin bei Patienten mit Morbus Parkinson und gastrointestinaler Resorptionsstörung - Fallbericht
Buhmann C
2010. Transdermales Rotigotin bei M. Parkinson und Restless-Legs Syndrom. Thieme-Verlag Stuttgart: 12-14.

Wann sollten wir mit der medikamentösen Therapie beim Morbus Parkinson beginnen?
Buhmann C, Klucken J, Korchounov A, Schwarz M, Vieregge P, Jost W
FORTSCHR NEUROL PSYC. 2010;78 Suppl 1:S31-3.

[When should we start medical treatment in Parkinson disease].
Buhmann C, Klucken J, Korchounov A, Schwarz M, Vieregge P, Jost W
FORTSCHR NEUROL PSYC. 2010;78(1):31-33.

Stalevo® zur Nacht bei Parkinson-Patienten
Buhmann C, Roscher T
Thieme Praxis Report. 2010;(1):1-18.

IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreement.
Derlin T, Afzal W, Wilke F, Apostolova I, Klutmann S, Meyer P, Buhmann C, Hesse S, Buchert R
NUKLEARMED-NUCL MED. 2010;49(4):139-147.

Nonmotor symptoms in genetic Parkinson disease.
Kasten M, Kertelge L, Brüggemann N, van der Vegt J, Schmidt A, Tadic V, Buhmann C, Steinlechner S, Behrens M, Ramirez A, Binkofski F, Siebner H, Raspe H, Hagenah J, Lencer R, Klein C
ARCH NEUROL-CHICAGO. 2010;67(6):670-676.

Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease.
Kertelge L, Brüggemann N, Schmidt A, Tadic V, Wisse C, Dankert S, Drude L, van der Vegt J, Siebner H, Pawlack H, Pramstaller P, Behrens M, Ramirez A, Reichel D, Buhmann C, Hagenah J, Klein C, Lohmann K, Kasten M
MOVEMENT DISORD. 2010;25(15):2665-2669.

Imaging movement-related activity in medicated Parkin-associated and sporadic Parkinson's disease.
van Eimeren T, Binkofski F, Buhmann C, Hagenah J, Strafella A, Pramstaller P, Siebner H, Klein C
PARKINSONISM RELAT D. 2010;16(6):384-387.

Gaze-Limb-Coordination in Parkinson Patients with STN Simulation driving in a Simulator
Zangemeister W, Maintz L, Hierling J, Buhmann C
ECEM (European congress of eye movements). 2010;Abstractband zum Kongreß:.

Effects of DBS, premotor rTMS, and levodopa on motor function and silent period in advanced Parkinson's disease.
Bäumer T, Hidding U, Hamel W, Buhmann C, Moll C, Gerloff C, Orth M, Siebner H, Münchau A
MOVEMENT DISORD. 2009;24(5):672-676.

State of the Art – M. Parkinson
Buhmann C
PharmaFokus ZNS. 2009;(6):24-27.

Therapie geriatrischer Patienten mit M. Parkinson
Buhmann C
AKTUEL NEUROL. 2009;36:312-319.

Equally normalized motor activation in medicated Parkin-associated and sporadic PD
Eimeren Van T, Buhmann C, Hagenah J, Pramstaller P, Siebner H, Klein C
MOVEMENT DISORD. 2009;(24):217.

Beeinträchtigung der Geruchs- und Farbwahrnehmung bei genetischen und nicht genetischen Parkinsonsyndromen
Tadic V, Kertelge L, Brüggemann N, Schmidt A, Wisse C, Drude L, van der Vegt J, Schneider S, Siebner H, Lohmann K, Buhmann C, Hagenah J, Klein C, Kasten M
AKTUEL NEUROL. 2009;(2):212.

Mapping preclinical compensation in Parkinson's disease: an imaging genomics approach
van Nuenen B, van Eimeren T, van der Vegt J, Buhmann C, Klein C, Bloem B, Siebner H
MOVEMENT DISORD. 2009;24 Suppl 2:S703-10.

Successful GPi deep brain stimulation in a patient with adult onset primary axial dystonia.
Zittel S, Moll C, Hamel W, Buhmann C, Engel A, Gerloff C, Münchau A
J NEUROL NEUROSUR PS. 2009;80(7):811-812.

Diagnostik und Therapie des M. Parkinson beim älteren Patienten
Buhmann C
Neurogeriatrie. 2008;5(4):135-143.

Initial experience with ropinirole PR (prolonged release).
Jost W, Buhmann C, Fuchs G, Greulich W, Hummel S, Korchounov A, Müngersdorf M, Schwarz M, Spiegel-Meixensberger M
J NEUROL. 2008;255(5):60-63.

Klinik, Differentialdiagnostik und Therapie des M. Parkinson
Buhmann C
focus neurogeriatrie. 2007;(4):2-8.

Pallidal neuronal activity in myoclonus-dystonia syndrome
Gulberti A, Moll C, Sharott A, Hamel W, Muenchau A, Buhmann C, Hidding U, Zittel S, Gerloff C, Westphal M, Müller D, Engel A
2007. IBAGS IX. .

arousal reaction due to electrical stimulation of the globus pallidus
Moll C, Sharrott A, Buhmann C, Hidding U, Zittel S, Westphal M, Hamel W, Engel A
ACTA PHYSIOL. 2007;189.

Contrasting Parkin-associated and sporadic parkinsonism with fMRI during internally and externally cued action
Eimeren Van T, Klein C, Buhmann C, Erdmann C, Büchel C, Binkofski F, Siebner H
HUM BRAIN MAPP. 2006.

MEP latency shift after implantation of deep brain stimulation systems in the subthalamic nucleus in patients with advanced Parkinson's disease.
Hidding U, Bäumer T, Siebner H, Demiralay C, Buhmann C, Weyh T, Moll C, Hamel W, Münchau A
MOVEMENT DISORD. 2006;21(9):1471-1476.

Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes.
Strekalova H, Buhmann C, Kleene R, Eggers C, Saffell J, Hemperly J, Weiller C, Müller-Thomsen T, Schachner M
NEUROBIOL AGING. 2006;27(1):1-9.

Role of functional imaging in neurological disorders.
Weiller C, May A, Sach M, Buhmann C, Rijntjes M
J MAGN RESON IMAGING. 2006;23(6):840-850.

Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism.
Buhmann C, Binkofski F, Klein C, Büchel C, van Eimeren T, Erdmann C, Hedrich K, Kasten M, Hagenah J, Deuschl G, Pramstaller P, Siebner H
BRAIN. 2005;128(10):2281-2290.

Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication.
Buhmann C, Arlt S, Kontush A, Möller-Bertram T, Sperber S, Oechsner M, Stuerenburg H, Beisiegel U
NEUROBIOL DIS. 2004;15(1):160-170.

Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
Buhmann C, Gorsler A, Bäumer T, Hidding U, Demiralay C, Hinkelmann K, Weiller C, Siebner H, Münchau A
BRAIN. 2004;127(12):2732-2746.

Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
Dong-Si T, Weber J, Liu Y, Buhmann C, Bauer H, Bendl C, Schnitzler P, Grond-Ginsbach C, Grau A
J NEUROL. 2004;251(5):542-547.

Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease.
Buhmann C, Bussopulos A, Oechsner M
MOVEMENT DISORD. 2003;18(2):219-221.

Pharmacologically modulated fMRI--cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients.
Buhmann C, Glauche V, Stürenburg H, Oechsner M, Weiller C, Büchel C
BRAIN. 2003;126(2):451-461.

CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity.
Ganzer S, Arlt S, Schoder V, Buhmann C, Mandelkow E, Finckh U, Beisiegel U, Naber D, Müller-Thomsen T
J NEURAL TRANSM. 2003;110(10):1149-1160.

Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10.
Gbadamosi J, Buhmann C, Tessmer W, Moench A, Haag F, Heesen C
EUR NEUROL. 2003;49(3):137-141.

Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone.
Heesen C, Bruegmann M, Gbadamosi J, Koch E, Mönch A, Buhmann C
MULT SCLER J. 2003;9(2):213-214.

Plasma amino acids in ecstasy users.
Stuerenburg H, Petersen K, Buhmann C, Rosenkranz M, Bäumer T, Thomasius R
NEUROENDOCRINOL LETT. 2003;24(5):348-349.

Increased lipid peroxidation in cerebrospinal fluid and plasma from patients with Creutzfeldt-Jakob disease.
Arlt S, Kontush A, Zerr I, Buhmann C, Jacobi C, Schröter A, Poser S, Beisiegel U
NEUROBIOL DIS. 2002;10(2):150-156.

Visual recovery in a man with the rare combination of mtDNA 11778 LHON mutation and a MS-like disease after mitoxantrone therapy.
Buhmann C, Gbadamosi J, Heesen C
ACTA NEUROL SCAND. 2002;106(4):236-239.

COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Oechsner M, Buhmann C, Strauss J, Stuerenburg H
J NEURAL TRANSM. 2002;109(1):69-75.

Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users.
Stuerenburg H, Petersen K, Bäumer T, Rosenkranz M, Buhmann C, Thomasius R
NEUROENDOCRINOL LETT. 2002;23(3):259-261.

Failure of ondansetron in treating cerebellar tremor in MS patients--an open-label pilot study.
Gbadamosi J, Buhmann C, Moench A, Heesen C
ACTA NEUROL SCAND. 2001;104(5):308-311.

Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS).
Gold S, Heesen C, Schulz H, Guder U, Mönch A, Gbadamosi J, Buhmann C, Schulz K
MULT SCLER J. 2001;7(2):119-130.

Characterization of four lipoprotein classes in human cerebrospinal fluid.
Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg H, Buhmann C, Beisiegel U
J LIPID RES. 2001;42(7):1143-1151.

IL-1ra serum levels in disease stages of MS--a marker for progression?
Heesen C, Sieverding F, Buhmann C, Gbadamosi J
ACTA NEUROL SCAND. 2000;101(2):95-97.

Workshop II: "neuroprotection"--the Lugano consensus.
Riederer P, Brücke T, Buhmann C, Müller T, Schwartz A, Storch A, Winner B
J NEUROL. 2000;247(4):36-37.

Increased lipoprotein oxidation in Alzheimer's disease.
Schippling S, Kontush A, Arlt S, Buhmann C, Stürenburg H, Mann U, Müller-Thomsen T, Beisiegel U
FREE RADICAL BIO MED. 2000;28(3):351-360.

Current status of multiple sclerosis therapy in Germany: a national survey.
Heesen C, Hauer S, Hadji-Abdolrahim B, Berenbeck C, Buhmann C, Emskotter T
EUR J NEUROL. 1999;6(1):35-38.

Computer-assisted three-dimensional reconstruction of the corticospinal system as a reference for CT and MRI.
Buhmann C, Kretschmann H
NEURORADIOLOGY. 1998;40(9):549-557.

[Three-dimensional reconstructions in neuroanatomy]
Kretschmann H, Vogt H, Schütz T, Gerke M, Riedel A, Buhmann C, Wesemann M, Müller D
RADIOLOGE. 1991;31(10):481-488.

Letzte Aktualisierung aus dem FIS: 03.11.2024 - 23:48 Uhr